Delivery Order SPE2DB22D2211-SPE2DB25FRJPZ

Award Date 11/8/24
Potential Completion Date 11/12/24
Potential Value $1.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,069.41 firm fixed-price delivery order is for the supply of 500 units of Bupropion HCL XL 150 mg tablets, a medication used for the treatment of depression and other mental health conditions. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
This federal contract award is a delivery order placed by the Defense Logistics Agency (DLA) with AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 150 mg Bupropion HCL XL tablets, a generic medication used for the treatment of depression. The award has a ceiling value of $1,160.61 and a completion date of December 12, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that...
This federal contract award, valued at $30,713.58, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 500-count bupropion HCL XL 300 mg tablets, a medication used to treat depression and other conditions. The contract has a completion date of February 7, 2024 and is a firm fixed-price delivery order. No set-aside designation was applied. AmerisourceBergen holds a significant Indefinite...
This federal contract award, valued at $58,566.11, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,564,286,845 units of Bupropion HCL XL 300 mg tablets, a generic medication used to treat depression and certain other conditions. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $27,015.60 fixed-price delivery order contract is for the supply of Bupropion HCL XL 150 mg tablets, a generic medication used to treat depression and other conditions. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp holds a $999,999,999...
This federal contract award, valued at $1,583.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for Bupropion HCL XL 300 mg Tablets, with an ultimate completion date of November 13, 2023. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen Drug Corp is the prime contractor, with no major subcontractors...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $43,688.03, is for the delivery of Bupropion HCL XL 300 mg tablets, a generic medication used to treat depression and nicotine addiction. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,068.28 firm-fixed-price delivery order is for the supply of Bupropion HCL XL 300 MG tablets. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award, with ID SPE2DB22D3301|SPE2DB24FX9DV, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Bupropion HCL XL 300 mg tablets, a generic medication used to treat depression and other conditions. The contract is a Firm Fixed Price Delivery Order, with a ceiling value of $21,578.51 and a completion date of January 23, 2024. It is not...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,487.12 firm fixed-price delivery order is for the supply of 4,567,379,185 units of Bupropion HCL XL 300 mg tablets. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB25FRJPZ
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,570.13 firm fixed-price delivery order is for the supply of Bupropion HCL XL 300 mg tablets, a medication used to treat depression and other conditions.

The award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract has no set-aside designation, indicating open competition. The contract has an ultimate completion date of November 12, 2024.

Generated 2/7/25, 9:21 AM